{"product_id":"vstm-ansoff-analysis","title":"(VSTM) Verastem, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExplore the Complete Growth Strategy Behind the Preview\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Verastem, Inc. Ansoff Matrix Analysis helps you quickly assess the company’s growth options across market penetration, market development, product development, and diversification in one concise framework; this page includes a real preview\/sample of the analysis so you can review style and substance before buying. Purchase the full version to receive the complete, ready-to-use company-specific report for strategy, investment, or planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRAMP 201 recurrent low-grade serous ovarian cancer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRAMP 201 is an adaptive, two-part, multicenter, randomized, open-label study in recurrent low-grade serous ovarian cancer, testing VS-6766 alone and with defactinib. This supports Verastem, Inc. market penetration by deepening its focus in a defined ovarian cancer niche already served by its pipeline.\u003c\/p\u003e\n\u003cp\u003eThe study design can expand clinical evidence in a rare disease segment where patient counts are limited, which matters for adoption and future label support.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVS-6766 and defactinib regimen\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDefactinib is an oral FAK inhibitor, and pairing it with VS-6766 stacks RAF\/MEK plus FAK blockade in one regimen. That widens Verastem, Inc.'s share of the same oncology space by deepening differentiation, not just broadening labels. In RAMP-201, the combo showed a 44% objective response rate in low-grade serous ovarian cancer, a clear proof point for market penetration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRAMP 202 mutation-defined NSCLC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVerastem, Inc.'s RAMP 202 Phase 2 study targets a sharp late-line NSCLC niche: patients with KRAS or BRAF mutations after platinum therapy and immune checkpoint inhibitors. NSCLC is about 85% of lung cancers, while KRAS mutations appear in roughly 25% of NSCLC and BRAF in about 2%, so the pool is small but clearly defined. That makes this a focused market penetration move, not a broad launch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRAMP 203 with Amgen LUMAKRAS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRAMP 203 is a Phase 1\/2 study of Verastem, Inc.'s VS-6766 with Amgen's LUMAKRAS, so it pushes the same lead asset into a new KRAS-G12C combo setting. This is market penetration in Ansoff terms: Verastem is deepening use cases in precision oncology instead of moving to a new drug class.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase 1\/2 combo trial\u003c\/li\u003e\n\u003cli\u003eExtends precision-oncology reach\u003c\/li\u003e\n\u003cli\u003eBuilds on VS-6766 data\u003c\/li\u003e\n\u003cli\u003eTargets KRAS-G12C biology\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eChugai VS-6766 commercialization rights\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVerastem has licensed development, manufacturing, and commercialization rights for VS-6766-based products to Chugai Pharmaceutical in Japan, giving the lead program a built-in route to market in a major pharma market. That setup widens future reach without Verastem funding a full local launch team. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChugai handles in-market execution.\u003c\/li\u003e\n\u003cli\u003eVerastem keeps pipeline reach via licensing.\u003c\/li\u003e\n\u003cli\u003eJapan rights support future penetration.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVerastem Deepens Oncology Reach with Strong RAMP 201 Signal\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVerastem, Inc. is using market penetration by pushing VS-6766 and defactinib deeper into rare oncology niches, especially recurrent low-grade serous ovarian cancer and KRAS\/BRAF-driven NSCLC. RAMP 201 posted a 44% objective response rate, which supports stronger use in the same disease pool.\u003c\/p\u003e\n\u003cp\u003eRAMP 202 and RAMP 203 extend the same precision-oncology base into defined late-line and KRAS-G12C settings, while Chugai’s Japan rights add a second route to adoption.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRAMP 201\u003c\/td\u003e\n\u003ctd\u003e44% ORR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRAMP 202\u003c\/td\u003e\n\u003ctd\u003eKRAS\/BRAF NSCLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRAMP 203\u003c\/td\u003e\n\u003ctd\u003eKRAS-G12C combo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eMaps Verastem, Inc.’s growth options across existing and new products and markets through the Ansoff Matrix\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a quick, clear Ansoff Matrix view for Verastem, Inc. to simplify growth planning and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable bibliography of primary and reputable sources to validate Verastem growth-path assumptions for Ansoff Matrix analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulticenter trial footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVerastem, Inc. uses multicenter trials to place the same asset in many oncology sites at once, widening investigator and patient access without changing the drug program. Its lead effort, avutometinib plus defactinib, moved through a global network of sites in 2025, which speeds enrollment and makes the same protocol visible to more centers. That is a direct market-development move: more sites, more reach, same core asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOvarian cancer niche expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVS-6766 is being tested in recurrent low-grade serous ovarian cancer, a rare subgroup that makes up about 6% of ovarian cancers. Verastem, Inc. is moving from a broad ovarian cancer theme into a narrower market with an existing asset, which fits market development in the Ansoff Matrix. With more than 20,000 U.S. ovarian cancer cases each year, even a small niche can still support meaningful revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiomarker-defined lung cancer entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVerastem, Inc.'s RAMP 202 targets KRAS- and BRAF-mutant NSCLC, a biomarker-defined slice of lung cancer that sits inside the ~85% of cases that are non-small cell. KRAS mutations appear in about 25% of NSCLC, while BRAF mutations are near 2%, so the same platform can enter a distinct, mutation-led market. This is market development: one therapy class, new tumor segment, and a sharper path to label expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLater-line NSCLC setting\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe NSCLC study enrolls patients after platinum-based regimens and immune checkpoint inhibitors, so Verastem, Inc. is moving the same asset into a later-line setting. That widens use across a new point in care, where post-progression options are still limited and treatment decisions shift to disease control and tolerability.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLater-line NSCLC market\u003c\/li\u003e\n\u003cli\u003ePost-platinum, post-ICI patients\u003c\/li\u003e\n\u003cli\u003eSame asset, new use case\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner commercialization channel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVerastem, Inc.'s Chugai deal gives Chugai commercialization and manufacturing rights, so VS-6766 can reach partner-led markets without Verastem building local sales or supply lines. That is a low-capex way to widen access to the same asset and keep capital focused on core programs.\u003c\/p\u003e\n\u003cp\u003eThis matters more after the May 2025 U.S. approval of avutometinib plus defactinib for recurrent KRAS-mutant low-grade serous ovarian cancer, which gives the franchise a real commercial base to export through partners. The model can scale faster than direct entry when a market needs local labeling, reimbursement, and manufacturing support.\u003c\/p\u003e\n\u003cp\u003eIn Ansoff terms, it is market development: same product, new geography, partner-led execution. One approved product can now serve more than one route to market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChugai handles local commercialization\u003c\/li\u003e\n\u003cli\u003eChugai also handles manufacturing rights\u003c\/li\u003e\n\u003cli\u003eVS-6766 expands beyond direct reach\u003c\/li\u003e\n\u003cli\u003eUses the same product in new markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVerastem Expands Its Oncology Franchise Into New Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVerastem, Inc. is using the same oncology assets in new diseases, lines of therapy, and geographies, which is classic market development. In 2025, avutometinib plus defactinib won U.S. approval for recurrent KRAS-mutant low-grade serous ovarian cancer, giving the franchise a live base to expand from.\u003c\/p\u003e\n\u003cp\u003eRAMP 202 also pushes the platform into post-platinum, post-ICI KRAS\/BRAF-mutant NSCLC, while Chugai gives local commercialization and manufacturing reach without a full U.S.-only buildout.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproval\u003c\/td\u003e\n\u003ctd\u003e1 U.S. label\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOvarian niche\u003c\/td\u003e\n\u003ctd\u003e~6% of cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNSCLC base\u003c\/td\u003e\n\u003ctd\u003e~85% of lung cancers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eVerastem, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDual RAF MEK clamp mechanism\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVS-6766 is Verastem, Inc.'s core innovation: a dual RAF\/MEK inhibitor that uses a clamp mechanism to block MEK kinase activity and RAF-driven MEK phosphorylation. That 2-target design gives the company a clear product-development edge inside the Ansoff Matrix, since it deepens the current pipeline with a differentiated molecule. It is the main value driver in Verastem's current oncology strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVS-6766 monotherapy arm\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRAMP 201 tests VS-6766 as a single agent in a Phase 1\/2 setting, so Verastem, Inc. can measure standalone activity without the noise of a partner drug. That fits Ansoff product development: it refines the same oncology asset inside the same market. The monotherapy arm also helps define response, dose, and tolerability before broader use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVS-6766 and defactinib combination product\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVerastem, Inc. is advancing VS-6766 with defactinib, a focal adhesion kinase inhibitor, as a new regimen for existing cancer markets. In RAMP-201, the combo produced a 44% objective response rate in recurrent low-grade serous ovarian cancer, supporting a product-development move with clear clinical use.\u003c\/p\u003e\n\u003cp\u003eThe addressable market is still meaningful: about 6,000 to 8,000 U.S. women live with this rare ovarian cancer subtype, and many need better options after platinum therapy. That makes the pair a practical line extension in oncology, not a new market bet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVS-6766 and LUMAKRAS combination\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRAMP 203 tests VS-6766 plus LUMAKRAS in KRAS-G12C tumors, creating a new combo around the same mutation target. It adds a second program to Verastem, Inc.'s combo-led pipeline, building on LUMAKRAS, the first FDA-approved KRAS G12C inhibitor in 2021. The pairing aims to deepen pathway blockade and widen clinical use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eKRAS-G12C focused pairing\u003c\/li\u003e\n\u003cli\u003eCombo-led pipeline expansion\u003c\/li\u003e\n\u003cli\u003eBuilt on LUMAKRAS approval\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePfizer FAK inhibitor rights\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVerastem’s Pfizer FAK inhibitor rights give it access to a second kinase class, so it can build new oncology products around the FAK pathway instead of starting from zero. FAK, or focal adhesion kinase, is a validated cancer target, and the license helps Verastem reuse Pfizer’s existing chemistry and know-how to cut early R\u0026amp;D risk. In Ansoff terms, this is product development: new drugs for the same cancer market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSecond inhibitor class access\u003c\/li\u003e\n\u003cli\u003eLower early discovery risk\u003c\/li\u003e\n\u003cli\u003eSupports FAK-based pipeline growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVerastem’s Pipeline Expands With Strong Combo Trial Momentum\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVerastem, Inc.’s product development centers on VS-6766, a dual RAF\/MEK inhibitor, and the company’s combo trials deepen the same oncology market instead of entering a new one. In RAMP 201, VS-6766 plus defactinib posted a 44% objective response rate in recurrent low-grade serous ovarian cancer.\u003c\/p\u003e\n\u003cp\u003eRAMP 203 extends the pipeline into KRAS-G12C tumors with LUMAKRAS, widening use of the same pathway logic. Pfizer FAK rights also give Verastem, Inc. a second kinase platform to build on.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVS-6766\u003c\/td\u003e\n\u003ctd\u003eCore asset\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRAMP 201\u003c\/td\u003e\n\u003ctd\u003e44% ORR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRAMP 203\u003c\/td\u003e\n\u003ctd\u003eKRAS-G12C combo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFAK inhibitor use cases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVerastem, Inc.’s FAK inhibitor diversification is broader because the Pfizer agreement spans 3 use cases: therapeutic, diagnostic, and prophylactic. That moves the asset beyond a single treatment format and can support more than 1 market path. In Ansoff terms, it widens both product scope and market reach for the collaboration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKRAS-G12C combination program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRAMP 203 pairs Verastem, Inc.'s VS-6766 with Amgen's LUMAKRAS, moving Verastem into the KRAS-G12C precision oncology space. This adds a second combo path beyond its lead MEK\/RAF program and broadens its Ansoff diversification. KRAS-G12C occurs in about 13% of NSCLC and 3% to 4% of colorectal cancer.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartner-led pipeline expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVerastem’s partner-led pipeline uses 3 active collaborators, Chugai, Pfizer, and Amgen, so development risk is split across multiple external programs. That matters for diversification: one deal can fail without sinking the whole pipeline, and each partner opens a separate path to licensing, milestones, or supply. The model widens Verastem’s product sources and market reach while limiting single-asset dependence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOvarian and lung cancer portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVerastem, Inc. is spreading risk across two oncology bets: recurrent low-grade serous ovarian cancer, about 5% of ovarian cancers, and NSCLC, which makes up about 80% to 85% of lung cancers. That mix lowers dependence on one disease area and widens the commercial base.\u003c\/p\u003e\n\u003cp\u003eThe portfolio has different clinical and payer paths, so one program can still add value if the other slows. In Ansoff terms, this is product diversification inside oncology, not a single-market push.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTwo separate cancer markets\u003c\/li\u003e\n\u003cli\u003eLower single-disease exposure\u003c\/li\u003e\n\u003cli\u003eBroader pipeline optionality\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCommercialization and manufacturing network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVerastem, Inc. gains diversification through the Chugai license because it covers development, commercialization, and manufacturing rights, so the Company is not tied to internal execution alone. That widens operational reach and lowers single-point risk across the VS-6766 asset chain.\u003c\/p\u003e\n\u003cp\u003eThe move can extend market access beyond a single launch path, which matters as VS-6766 advances into broader oncology use. In Ansoff terms, this is a stronger route to product-market expansion with shared control over supply and go-to-market execution.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLicense spans development, commercialization, manufacturing\u003c\/li\u003e\n\u003cli\u003eAdds reach beyond internal execution\u003c\/li\u003e\n\u003cli\u003eSupports wider VS-6766 market footprint\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVerastem Spreads Risk Across Partners and Expands Its Oncology Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVerastem, Inc. uses diversification by spreading oncology risk across 3 partners: Chugai, Pfizer, and Amgen. VS-6766 now covers recurrent low-grade serous ovarian cancer, about 5% of ovarian cancers, plus KRAS-G12C tumors in about 13% of NSCLC and 3% to 4% of colorectal cancer.\u003c\/p\u003e\n\u003cp\u003eThat widens product scope, market reach, and deal optionality beyond a single asset.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDriver\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003cth\u003eAnsoff read\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartners\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003ctd\u003eRisk spread\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLGSC share\u003c\/td\u003e\n\u003ctd\u003e~5%\u003c\/td\u003e\n\u003ctd\u003eDisease focus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKRAS-G12C\u003c\/td\u003e\n\u003ctd\u003e13% NSCLC; 3%-4% CRC\u003c\/td\u003e\n\u003ctd\u003eMarket expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235161841929,"sku":"vstm-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/vstm-ansoff-matrix.webp?v=1785735649","url":"https:\/\/dcfanalyst.com\/products\/vstm-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}